AgingResearch.NewsJoin free

DR5 car-nk cells

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Basic and Applied Basic Research Foundation of Guangdong Province and 3 more
  • Animals1

Outcomes

3

Senescent NK cells

downin human cells1

1 study

  1. DR5 car-nk cells decrease senescent NK cells in human cells.

    “selective elimination of DR5-expressing senescent NK cells that acted as inadvertent feeder cells.”

    Cellsin culture

    DR5 CAR-NK cells demonstrate superior scalability and potent antitumor activity with favorable safety

    Molecular therapy : the journal of the American Society of Gene Therapy16 Oct 2025

More on Senescent NK cells

Cell killing (cytotoxicity)

upin human cells1

1 study

  1. DR5 car-nk cells induce cell killing (cytotoxicity) in human cells.

    “In vitro, the engineered NK cells potently killed DR5+ tumor cells through direct cytolysis and DR5-mediated apoptosis, even under exhaustion-like conditions.”

    Cellsin vitro

    DR5 CAR-NK cells demonstrate superior scalability and potent antitumor activity with favorable safety

    Molecular therapy : the journal of the American Society of Gene Therapy16 Oct 2025

More on Cell killing (cytotoxicity)

Tumor growth

downin mice1

1 study

  1. DR5 car-nk cells decrease tumor growth in mice.

    “In vivo, they suppressed tumor growth in xenograft models without observable toxicity to normal tissues, despite their recognition of murine DR5.”

    Animalsin xenograft models

    DR5 CAR-NK cells demonstrate superior scalability and potent antitumor activity with favorable safety

    Molecular therapy : the journal of the American Society of Gene Therapy16 Oct 2025

Latest

Related